Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $160.4 million.

  • Mirum Pharmaceuticals' Total Current Liabilities rose 38.54% to $160.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.4 million, marking a year-over-year increase of 38.54%. This contributed to the annual value of $126.6 million for FY2024, which is 45.35% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Total Current Liabilities is $160.4 million, which was up 10.75% from $144.8 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Total Current Liabilities' 5-year high stood at $160.4 million during Q3 2025, with a 5-year trough of $29.0 million in Q2 2021.
  • Its 3-year average for Total Current Liabilities is $105.6 million, with a median of $112.3 million in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 168.13% in 2021, then dropped by 1.34% in 2022.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Total Current Liabilities stood at $42.6 million in 2021, then skyrocketed by 51.96% to $64.7 million in 2022, then skyrocketed by 34.51% to $87.1 million in 2023, then surged by 45.35% to $126.6 million in 2024, then spiked by 38.54% to $160.4 million in 2025.
  • Its last three reported values are $160.4 million in Q3 2025, $144.8 million for Q2 2025, and $127.6 million during Q1 2025.